Exosomes-mediated tumor metastasis through reshaping tumor microenvironment and distant niche

Luo, Xinyi; Li, Yang; Hua, Zhenglai; Xue, Xiaoxia; Wang, Xiangpeng; Pang, Mingshi; Xiao, Cheng; Zhao, Hongyan; Lyu, Aiping; Liu, Yuanyan

doi:10.1016/j.jconrel.2022.11.050

Cited by 32 publications

(18 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastasis is stimulated and controlled by intercellular communication in endothelial cells [115]. By interfering with their direct and indirect communication mediators against endothelial changes, both stages can be inhibited [116].…”

Section: Interfere Communication Mediators' Therapiesmentioning

confidence: 99%

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance

Zaidi¹,

Haque²,

Miskon³

2023

Preprint

View full text Add to dashboard Cite

There has been no significant efficacy in treatment for osteosarcoma (OS) metastasis after nearly four decades of trials. This motivates us to elucidate OS therapies according to their four bidirectional mutation stages. To refresh the OS therapy status quo, the historical developments and clinical advancements are briefly described. However, the main issue of metastasis remains unresolved, accounting for 90% of pulmonary metastasis deaths. Thus, this metastasis problem is related to immune evasion and chemoresistance that are being induced after long-term treatment by the use of immunotherapy for tumorigenesis. Therefore, it is rationale to discuss the relationship cycles of mutation stages including tumorigenesis, metastasis, immune evasion, and chemoresistance. Even though many combinational and targeted therapies have been developed to intensify these mutation treatments, successful clinical translations with higher cure rates are still rare. Through this review, an in-depth understanding of the bidirectional relationship between the four OS mutation stages and their respective therapies is provided. Herein, we summarise the medicines used to treat tumorigenesis, including COLGALT2 inhibitors, Tra2B, and AGAP1, miR-148a and miR-21-5p EVs, and the lncRNA LIFR-AS1. Following the medicines used to treat metastasis are AXL, miR-135a-5p, mRNA BCL6, TGFβ1, Tim-3, SOCS5, CASC15, KLF3-AS1, PDCD4, ATG5, and Rab22a-NeoF1. Then the medicines used to treat immune evasion are N-cadherin, anti-IL-9, USP12 inhibitor, IgG-4+ B-cells, LAP inhibitor, anti-Wnt2 mAb, anti-αvβ8 integrin, HK2-mediated IκBα, IDO inhibitor with NO, and TGF-βRII with anti-IgG1. Finally, the medicines used to treat chemoresistance are DHFR, FPGS, HSP-90AA1, XCT-790, ATKI, and IGF1. As a result, this contribution is expected to serve as a reference and guide for scientists and clinicians.

show abstract

Section: Interfere Communication Mediators' Therapiesmentioning

confidence: 99%

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance

Zaidi¹,

Haque²,

Miskon³

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…However, the useful data on tumour biology resulted in a better understanding of the signalling networks that control tumour growth and maintenance [41]. IGF1R, HER2, oestrogen receptor, IGF1R, PI3K/AKT, mTOR, AMPK, and angiogenesis pathways lead to the development of new targeted therapeutics [42].…”

Section: Molecular Biology In Breast Cancer: Intrinsic Subtypes and S...mentioning

confidence: 99%

Solid Lipid Nanoparticles: A Review on Different Techniques and Approaches to Treat Breast Cancer

GAJBHIYE¹,

Patil²

2023

Int J App Pharm

View full text Add to dashboard Cite

Breast cancer, the most common malignancy among women, is also the second-leading cause of cancer deaths all over the world. As commonly used chemotherapy drugs, which are given systematically, causes toxicity not only to cancerous cells but also to proliferating normal cells. Similarly, drug resistance leads to drastic side effects and treatment failure. Thus arises the need for improving the therapeutic index of anticancer drugs. Owing to these failures, nanotechnology holds significant promises. Using keywords like multi-drug resistance, effective targeting, therapeutics, intracellular pathways, efficacy, and breast cancer, references were looked up from specialised databases including Elsevier, Pubmed, and Cambridge from the year 1994 to 2023. This review was supplemented by a few references from Springer Nature and pertinent data from an online source. Along with online articles from Medscape, StatPearls, and The Lancet Respiratory Medicine, it was excellent. Supported literature was used to overcome these challenges; therapeutic drugs are encapsulated in nanoparticles. Concurrently, solid lipid nanoparticles (SLN), with their few merits, like enhancing the therapeutic profile, overcoming multidrug resistance, providing a targeted approach, and serving as a controlled release, have gained the attention of researchers. SLNs confine significant promises, overcome these challenges, and help to possibly deliver the drug to a specific part of the body, particular organ, or tissue by an actively or passively targeted delivery system, which will be beneficial in the diagnosis and treatment of breast cancer. The objective of this article is to highlight the factors that influence the targeted drug delivery system and resultant bioavailability and also provide updates on recent research and various approaches used for breast drug delivery systems.

show abstract

“…Exosomal miRNAs exert pleiotropic impacts on breast cancer hallmarks and clinical implications. ( Luo et al (2023) revealed the role of tumor-derived exosomes as a messenger and communicator between tumor cells and their microenvironment that can reshape and enhance tumor development and metastasis. They enhance the development of the pre-metastatic niche to promote tumor colonization and play a pivotal role in the early diagnosis and evaluation of future metastatic development ( Luo et al, 2023 ).…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

“…( Luo et al (2023) revealed the role of tumor-derived exosomes as a messenger and communicator between tumor cells and their microenvironment that can reshape and enhance tumor development and metastasis. They enhance the development of the pre-metastatic niche to promote tumor colonization and play a pivotal role in the early diagnosis and evaluation of future metastatic development ( Luo et al, 2023 ). Exosomes are used as drug carriers (e.g., chemotherapy and miRNA) and as biomarkers because they exhibit antigen-presenting traits that have a crucial function in cancer immunotherapy ( Hosseinikhah et al, 2023 ).…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Exosomal miRNAs as novel avenues for breast cancer treatment

et al. 2023

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed cancer and a leading cause of death in women worldwide. It is a heterogeneous disease, as shown by the gene expression profiles of breast cancer samples. It begins in milk-producing ducts, with a high degree of diversity between and within tumors, as well as among cancer-bearing individuals. The enhanced prevalence of breast cancer is influenced by various hormonal, lifestyle, and environmental factors, and very early onset of the disease correlates strongly with the risk of local and distant recurrence. Many subtypes are difficult to treat with conventional therapeutic modalities, and therefore, optimal management and early diagnosis are the first steps to minimizing the mortality linked with breast cancer. The use of newer methods of nanotechnology extends beyond the concept of synthesizing drug delivery mechanisms into the creation of new therapeutics, such as delivering chemotherapeutics with nanomaterial properties. Exosomes, a class of nanovesicles, are emerging as novel tools for deciphering the patient-specific proteins and biomarkers across different disease models, including breast cancer. In this review, we address the role of exosomal miRNA in breast cancer diagnosis and treatment.

show abstract

Exosomes-mediated tumor metastasis through reshaping tumor microenvironment and distant niche

Cited by 32 publications

References 133 publications

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance

Solid Lipid Nanoparticles: A Review on Different Techniques and Approaches to Treat Breast Cancer

Exosomal miRNAs as novel avenues for breast cancer treatment

Contact Info

Product

Resources

About